- The VC firm behind Algolia, Qonto and Stripe has never led a preventive health deal until now, backing Paris-based Lucis with a $20M Series A
- Singular’s bet signals a deliberate move into health data as the next infrastructure category, following the same pattern that made it an early conviction investor in SaaS and fintech
- Lucis has 10,000 users, 1M+ biomarker tests run, and 75% of users improving key health markers within six months, without medication
Singular built its reputation on infrastructure and fintech, the firm’s founding partners, Jeremy Uzan and Raffi Kamber, cut their teeth backing Algolia, Qonto, and co-investing in Stripe at Alven before spinning out their own firm, which has raised over €625M across two funds. Their pattern is consistent: find a category where data compounds into a structural advantage, and back the team building the layer that everyone else will eventually depend on. This week, for the first time at scale in preventive health, they applied that same logic to human biology.
Now, Singular has led a $20 million Series A into Lucis, a Paris-based preventive health platform founded in 2025 by Maxime Berthelot and Baptiste Debever. General Catalyst and Y Combinator also participated, alongside angels including early investors in Runna (since acquired by Strava). The round brings Lucis’s total funding to $28 million, the bulk raised in roughly five months, following an $8.5M seed in December 2025.
The infrastructure argument for health data
Singular describes itself as a generalist firm that runs “deep dive sprints” into emerging sectors rather than committing to a fixed thesis. Its previous health bet — leading the €30M Series A in German telehealth platform Formel Skin in 2022 (subsequently acquired by Manual in December 2025) — was reactive care: patients arriving with a skin condition, getting diagnosed and treated digitally. Lucis is a different kind of bet entirely. It sits upstream of the medical system, collecting longitudinal biomarker data before symptoms appear, and using that accumulating dataset to guide behaviour over months and years.
That distinction matters for how Singular thinks about defensibility. In SaaS infrastructure, the moat is the data that flows through the platform over time. Lucis is building the same thing in health: the longer a user stays on the platform, the richer and harder to replicate their personal health record becomes. Uzan’s framing in the investor quote — “a compounding data advantage” — is the same language Singular uses to describe why Algolia and Qonto were category winners. He is making a structural argument, not a wellness trend argument.
“Europe’s preventive health category will be won by platforms that unite clinical credibility with AI at scale,” said Uzan. “Lucis has moved with remarkable velocity, reaching 10,000 users in under a year, delivering measurable outcomes and building a compounding data advantage that sets the standard for the category. We see Lucis as a clear category winner in Europe.”
What Lucis actually does
Lucis analyses more than 110 blood biomarkers — spanning metabolic health, hormones, cardiovascular risk, inflammation, and nutrients — through certified partner labs including Eurofins and Randox. Results feed into an AI health coach that generates personalised guidance on nutrition, supplementation, sleep, and lifestyle. Physicians review every recommendation. The platform tracks changes over time; it is designed for the follow-up, not the one-off test.
The founding story behind it is less polished than the pitch. Berthelot had spent years quietly running his own experiments, ordering tests and tracking biomarkers in spreadsheets, trying to make sense of what any of it meant for his long-term health. Debever started searching for answers after a close relative passed away due to a late diagnosis. The two co-founders, along with Max Guerois, found each other through longevity communities in Paris, comparing notes on lab results and protocols. None of them come from a traditional medical background.
“We’ve seen the devastating impact of late-stage diagnosis first-hand,” said Berthelot. “The science is already there; what’s missing is a system designed to act before symptoms appear. Europe deserves a healthcare model that doesn’t wait for people to get sick. We are making prevention the default, rather than a privilege.”
The numbers so far
Early data from Lucis’s 10,000 users is striking in a way that most consumer health platforms cannot show. Among those completing a six-month follow-up, 75% improved at least three biomarkers without medication. More than 80% chose to retest, a measure of sustained engagement that directly supports the longitudinal data thesis Singular is backing. At initial testing, 99.9% discovered at least one biomarker outside optimal ranges, often without prior awareness.
That last number also defines the market case. Chronic conditions account for 74% of global deaths and 86% of healthcare spending in high-income countries, yet prevention programs command less than 3% of budgets. In Europe specifically, around 1.8 million deaths a year are classified as avoidable and linked to chronic disease. The global preventive healthcare market is projected to grow from $330 billion in 2025 to over $1 trillion by 2035, at a CAGR exceeding 11.8%.
The competitive picture
The US has moved faster on this model. Function Health raised $298M at a $2.5B valuation in late 2025 and had reached over 200,000 members by May of that year. Superpower Health, which acquired Base in mid-2025, has raised $34M including a $30M Series A in April 2025 led by Forerunner Ventures. LetsGetChecked raised $165M in the UK at the start of 2025.
In Europe, the competition is thinner but moving.Neko Health, the Spotify founder-backed preventive health platform, raised $260M led by Lightspeed in January 2025, but focuses on full-body imaging rather than longitudinal blood biomarker tracking. Ahead Health raised $6M in early 2026 for AI biomarker analysis. Lucis’s differentiation is clinical integration at scale: lab partnerships across four European markets, physician review embedded in the product, and a data model designed around continuity rather than snapshots.
Lucis currently operates in France, the UK, Ireland, and Portugal, with 10,000 users and over a million biomarker tests delivered. Spain, Germany, and Italy are targeted by the end of 2026. The company employs 20 people, with a medical board and a network of 10-plus physicians providing clinical oversight.
What the Singular bet signals
Singular runs “deep dive sprints” into emerging spaces when the timing and talent align and leads with conviction when it commits. The firm has deployed that approach in SaaS, fintech, and climate. Lucis is its clearest statement yet that it views preventive health data as the next category where the infrastructure layer remains unbuilt in Europe.
Whether Singular is early, right, or both on that thesis will take years to know. But for a fund that started in Algolia’s basement and built its track record on finding compounding data businesses before their categories were obvious, the direction of travel is clear.
The question for the European preventive health space is whether there is one infrastructure winner or several and whether the data advantage Lucis is accumulating now will prove hard enough to replicate when larger capital arrives.
